Eyegate (EYEG) Surges on New 'Buy' Rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Rodman & Renshaw Starts Eyegate Pharmaceuticals (EYEG) at Buy
February 1, 2016 7:32 AM ESTRodman & Renshaw initiated coverage on Eyegate Pharmaceuticals (NASDAQ: EYEG) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on Eyegate Pharmaceuticals click here. For more ratings news on Eyegate Pharmaceuticals click here.
Shares of Eyegate Pharmaceuticals closed at $1.70 yesterday.
... More